Literature DB >> 19821824

Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom.

C Mark Taylor1, Sam Machin, Stephen J Wigmore, Tim H J Goodship.   

Abstract

Atypical haemolytic uraemic syndrome (aHUS) is associated with a poor prognosis with regard to survival at presentation, recovery of renal function and transplantation. It is now established that aHUS is a disease of complement dysregulation with mutations in the genes encoding both complement regulators and activators, and autoantibodies against the complement regulator factor H. Identification of the underlying molecular abnormality in an individual patient can now help to guide their future management. In these guidelines we make recommendations for the investigation and management of aHUS patients both at presentation and in the long-term. We particularly address the role of renal transplantation alone and combined liver-kidney transplantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19821824     DOI: 10.1111/j.1365-2141.2009.07916.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  60 in total

Review 1.  [Thrombophilic states in intensive care medicine].

Authors:  L Engelmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2011-10-28       Impact factor: 0.840

2.  Thrombotic microangiopathy: atypical HUS: current diagnostic and therapeutic approaches.

Authors:  Alejandra Rosales; Magdalena Riedl; Lothar B Zimmerhackl
Journal:  Nat Rev Nephrol       Date:  2010-09       Impact factor: 28.314

3.  Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome.

Authors:  Olga Nikolajeva; Austen Worth; Rosie Hague; Nuria Martinez-Alier; Joanne Smart; Stuart Adams; E Graham Davies; H Bobby Gaspar
Journal:  J Clin Immunol       Date:  2015-04-15       Impact factor: 8.317

4.  Atypical HUS caused by anti-complement factor H antibody: a hematologist's perspective.

Authors:  Meet Kumar; Prakas Mandal; Rajib De; Pinaki Mukherjee; Tuphan Kanti Dolai; Maitryee Bhattyacharyya
Journal:  Blood Res       Date:  2015-03-24

5.  Different factor H-related protein patterns in siblings with typical hemolytic uremic syndrome.

Authors:  Marcus R Benz; Holger Schmid; Stefan Heinen; Bärbel Lange-Sperandio; Julia Hoefele; Thomas Sitter; Peter F Zipfel; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2011-04-21       Impact factor: 3.714

6.  Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Authors:  Elena Bresin; Erica Rurali; Jessica Caprioli; Pilar Sanchez-Corral; Veronique Fremeaux-Bacchi; Santiago Rodriguez de Cordoba; Sheila Pinto; Timothy H J Goodship; Marta Alberti; David Ribes; Elisabetta Valoti; Giuseppe Remuzzi; Marina Noris
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

Review 7.  Atypical hemolytic uremic syndrome.

Authors:  Vahid Afshar-Kharghan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

8.  Atypical HUS: time to take stock of current guidelines and outcome measures?

Authors:  Lesley Rees
Journal:  Pediatr Nephrol       Date:  2013-02-07       Impact factor: 3.714

Review 9.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

Review 10.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.